PPI and H2 Receptor Antagonist Use and Risk of Liver Cancer

08:00 EDT 2 Aug 2018 | Medscape

Do PPIs and H2 receptor antagonists contribute to the risk of primary liver cancer?
Alimentary Pharmacology & Therapeutics

Original Article: PPI and H2 Receptor Antagonist Use and Risk of Liver Cancer

More From BioPortfolio on "PPI and H2 Receptor Antagonist Use and Risk of Liver Cancer"